Lexicon Pharmaceuticals (LXRX) Jefferies London Healthcare Conference 2024 summary

Strategic program updates

• Multiple programs are approaching key decision points, including a sodium-glucose cotransporter for heart failure, type 1 diabetes, and hypertrophic cardiomyopathy, with a PDUFA date set for December 20 for type 1 diabetes.

• The SONATA trial for hypertrophic cardiomyopathy is underway, targeting a significant unmet need, with data expected by the end of 2026.

• The LX9211 phase 2b study for diabetic peripheral neuropathic pain is fully enrolled, with results anticipated in Q1 2025.

• LX9851, an oral weight management candidate, is progressing through IND-enabling studies, aiming for IND submission mid-next year.

• Resource allocation has been optimized, with some programs deprioritized to maximize value for stakeholders.

Type 1 diabetes program and regulatory outlook

• The sodium-glucose cotransporter program for type 1 diabetes targets a subgroup with GFR 60-90, potentially expanding the addressable population to 600,000 patients.

• Strong support from patient and medical communities was evident during the AdCom, with significant public engagement.

• Despite mixed AdCom feedback, ongoing collaboration with the FDA continues, with a final decision expected by December 20.

• Preparations for commercial launch are complete, leveraging existing infrastructure, with launch readiness anticipated for Q1 if approved.

• The program could become the first approved oral agent for glycemic management in type 1 diabetes with CKD.

Neuropathic pain program (LX9211)

• LX9211 is a non-opioid oral therapy for neuropathic pain, with phase 2b data expected in Q1 2025.

• The phase 2b trial is over-enrolled, with a four-arm design testing multiple dosing regimens.

• Trial design minimizes placebo response and allows concomitant use of standard therapies like gabapentin.

• Safety concerns such as dizziness have been addressed by modifying dosing to avoid high CMAX spikes.

• Positive results could position the program for partnering opportunities and support pivotal phase 3 trials.